This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2017 Jun 1;376(22):2168-2181.

doi: 10.1056/NEJMra1406186.

Myeloproliferative Neoplasms

Jerry L Spivak¹

Affiliations

PMID: 28564565
DOI: 10.1056/NEJMra1406186

Review

Myeloproliferative Neoplasms

Jerry L Spivak. N Engl J Med. 2017.

. 2017 Jun 1;376(22):2168-2181.

doi: 10.1056/NEJMra1406186.

Author

Jerry L Spivak¹

Affiliation

¹ From the Hematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore.

PMID: 28564565
DOI: 10.1056/NEJMra1406186

No abstract available

PubMed Disclaimer

Comment in

Myeloproliferative Neoplasms.
Nand S. Nand S. N Engl J Med. 2017 Aug 31;377(9):895. doi: 10.1056/NEJMc1708485. N Engl J Med. 2017. PMID: 28854087 No abstract available.
Myeloproliferative Neoplasms.
Barbui T, Thiele J, Tefferi A. Barbui T, et al. N Engl J Med. 2017 Aug 31;377(9):894-5. doi: 10.1056/NEJMc1708485. N Engl J Med. 2017. PMID: 28858464 No abstract available.

Similar articles

[Management strategy for BCR-ABL negative myeloproliferative neoplasms].
Gotoh A, Komatsu N. Gotoh A, et al. Rinsho Ketsueki. 2014 Jan;55(1):56-65. Rinsho Ketsueki. 2014. PMID: 24492037 Review. Japanese. No abstract available.
[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L. Schwarz J, et al. Vnitr Lek. 2011 Feb;57(2):189-213. Vnitr Lek. 2011. PMID: 21416861 Review. Czech.
Chronic myeloproliferative neoplasms in the elderly.
Maffioli M, Orlandi E, Passamonti F. Maffioli M, et al. Eur J Intern Med. 2018 Dec;58:33-42. doi: 10.1016/j.ejim.2018.05.005. Epub 2018 May 22. Eur J Intern Med. 2018. PMID: 29793825 Review.
[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A. Rajnai H, et al. Orv Hetil. 2006 Nov 12;147(45):2175-9. Orv Hetil. 2006. PMID: 17402211 Hungarian.
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL, Marton E, Plander M. Iványi JL, et al. Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226. Orv Hetil. 2011. PMID: 22011365 Hungarian.

See all similar articles

Cited by

Myeloproliferative Neoplasms and Cardiovascular Disease: A Review.
Leiva O, Liu O, Zhou S, How J, Lee M, Hobbs G. Leiva O, et al. Curr Treat Options Oncol. 2024 Oct;25(10):1257-1267. doi: 10.1007/s11864-024-01255-8. Epub 2024 Sep 16. Curr Treat Options Oncol. 2024. PMID: 39278999 Review.
IDH2 mutation accelerates TPO-induced myelofibrosis with enhanced S100a8/a9 and NFκB signaling in vivo.
Lin CC, Yao CY, Wang YH, Hsu YC, Yuan CT, Chen TC, Hsu CL, Lee SH, Lee JY, Shih PT, Kao CJ, Chuang PH, Kuo YY, Hou HA, Chou WC, Tien HF. Lin CC, et al. EJHaem. 2024 Jul 28;5(4):738-748. doi: 10.1002/jha2.983. eCollection 2024 Aug. EJHaem. 2024. PMID: 39157630 Free PMC article.
Computing cell state discriminates the aberrant hematopoiesis and activated microenvironment in Myelodysplastic syndrome (MDS) through a single cell genomic study.
Guo X, Jin W, Wen Y, Wang Z, Ren X, Liu Z, Fu R, Cai Z, Li L. Guo X, et al. J Transl Med. 2024 Jul 20;22(1):673. doi: 10.1186/s12967-024-05496-x. J Transl Med. 2024. PMID: 39033303 Free PMC article.
DARS expression in BCR/ABL1-negative myeloproliferative neoplasms and its association with the immune microenvironment.
Xiong H, Liao M, Zhang H, Li Y, Bai J, Zhang J, Li L, Zhang L. Xiong H, et al. Sci Rep. 2024 Jul 19;14(1):16711. doi: 10.1038/s41598-024-67067-w. Sci Rep. 2024. PMID: 39030308 Free PMC article.
Multi-omics differences in the bone marrow between essential thrombocythemia and prefibrotic primary myelofibrosis.
Zhang A, Sun T, Yu D, Fu R, Liu X, Xue F, Liu W, Ju M, Dai X, Dong H, Gu W, Chen J, Chi Y, Li H, Wang W, Yang R, Chen Y, Zhang L. Zhang A, et al. Clin Exp Med. 2024 Jul 8;24(1):154. doi: 10.1007/s10238-024-01350-y. Clin Exp Med. 2024. PMID: 38972952 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations